ArticleJournal of the American Veterinary Medical Association2015
Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012).
Article in Journal of the American Veterinary Medical Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines.Veterinary and comparative oncology · 2026Article
- Molecular Characterization of Hotspot Mutations in HER2, BRAF, KRAS, and PIK3CA in Canine Pulmonary Adenocarcinoma from Japan.Veterinary sciences · 2026Article
- Survival analysis of different treatment modalities and associated outcomes for canine primary pulmonary carcinoma.Frontiers in veterinary science · 2026Article
- Molecular Classification Based on the Gene Expression Profiles in Canine Histiocytic Sarcoma Cells.Veterinary and comparative oncology · 2025Article
- Article
- Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma.The Journal of veterinary medical science · 2024Article
- Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology.Frontiers in veterinary science · 2024Review
- Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma.Veterinary sciences · 2023Article
- Chemosensitivity of three patient-derived primary cultures of canine pericardial mesothelioma by single-agent and combination treatment.Frontiers in veterinary science · 2023Article
- Comparison of the Clinical Characteristics of Histiocytic Sarcoma in Bernese Mountain Dogs and Flat-Coated Retrievers.Veterinary sciences · 2022Article
- Computed tomography radiomic features hold prognostic utility for canine lung tumors: An analytical study.PloS one · 2021Article
- Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use.International journal of nanomedicine · 2020Review
- A Contemporary Retrospective Study of Survival in Dogs With Primary Lung Tumors: 40 Cases (2005-2017).Frontiers in veterinary science · 2020Article
- In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers.Veterinary and comparative oncology · 2018Article
- Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition?The Journal of small animal practice · 2017Article
- Canine Histiocytic Malignancies-Challenges and Opportunities.Veterinary sciences · 2016Review
- Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols.Open veterinary journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo evaluate the effectiveness of vinorelbine in the management of various malignant tumor types in dogs.
designRetrospective case series. ANIMALS: 58 dogs with malignant tumors, including pulmonary carcinoma (n = 31), histiocytic sarcoma (9), mast cell tumor (5), lymphoma (4), melanoma (2), and 7 other tumor types (1 each). PROCEDURES: Medical records of dogs treated with vinorelbine from December 1997 to December 2012 were reviewed for data regarding signalment, clinical signs, physical examination findings, clinicopathologic test results, diagnostic imaging results, vinorelbine doses and dose frequency, surgery and radiotherapy details when applicable, other chemotherapeutics administered, and outcomes. Descriptive, comparative, and survival statistics were computed for all dogs and for dogs by histologic subgroup of tumors.
resultsVinorelbine was administered palliatively to 44 (76%) dogs. One (2%) dog had a complete response for 162 days, 5 (11%) dogs had a partial response for a median duration of 91 days, 19 (43%) dogs had stable disease for a median duration of 68 days, and 19 (43%) dogs developed progressive disease after a median duration of 21 days. Clinical benefit was more difficult to assess in the remaining 14 (24%) dogs that received vinorelbine as an adjuvant treatment. Overall median time to tumor progression was 103 days (range, 5 to 1,533 days). CONCLUSIONS AND CLINICAL RELEVANCE: Vinorelbine appeared to be effective in the treatment of several tumor types in dogs. Follow-up prospective studies of the clinical benefit of the drug in specific clinical scenarios will be necessary to support this conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.